Rovalpituzumab tesirine
Rovalpituzumab tesirine (pronunciation: roh-val-pi-TOO-zoo-mab te-SEER-een) is a monoclonal antibody-drug conjugate designed for the treatment of small cell lung cancer (SCLC).
Etymology
The name "Rovalpituzumab tesirine" is derived from the components of the drug. "Rova" refers to the targeting component, a monoclonal antibody that binds to delta-like protein 3 (DLL3), "pituzu" is a stem used in World Health Organization (WHO) International Nonproprietary Names (INN) for monoclonal antibodies, and "mab" indicates that it is a monoclonal antibody. "Tesirine" refers to the cytotoxic agent that is conjugated to the antibody.
Mechanism of Action
Rovalpituzumab tesirine works by binding to the DLL3 protein, which is overexpressed in SCLC. Once bound, the drug is internalized into the cancer cell where the cytotoxic agent is released, causing cell death.
Related Terms
- Monoclonal antibody
- Small cell lung cancer
- Delta-like protein 3
- Cytotoxic agent
- World Health Organization
- International Nonproprietary Names
See Also
External links
- Medical encyclopedia article on Rovalpituzumab tesirine
- Wikipedia's article - Rovalpituzumab tesirine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski